The Lake Forest, Calif.-based company reported profits of $3.3 million, or 7¢ per share, on sales of $46 million for the three months ended Jan. 1, 2021, for a bottom-line loss of -47.8% sales growth of 18.3% compared with Q4 2019.
Adjusted to exclude one-time items, earnings per share were 14¢, 4¢ ahead of The Street, where analysts were looking for sales of $44.5 million.
“Our 2020 performance reflects the continued momentum behind Staar’s commercial growth and product innovation. Consequently, we achieved strong fourth-quarter results and met our original sales targets for the second half of 2020, despite the unprecedented global pandemic. Our momentum has continued into the first weeks of 2021,” president and CEO Caren Mason said in a news release.
Staar Surgical did not provide a financial outlook for 2021.
Shares in STAA were down -3.36% to $111 apiece in pre-market trading.